ARPE-19 as a platform cell line for encapsulated cell-based delivery
US6361771B1 · kind B1 · utility
47Cited by
18References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2000 |
| Grant date | Mar 26, 2002 |
| Priority date | — |
| Expiry date | Apr 5, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/128
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
ARPE-19 cells were evaluated as a platform cell line for encapsulated and un-encapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; has a long life span; is of human origin; has good in vivo device viability; delivers efficacious quantity of growth factor; triggers no or low level host immune reaction, and is non-tumorigenic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.